Skip to main content
Top
Published in: BMC Medicine 1/2009

Open Access 01-12-2009 | Research article

Recent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status

Published in: BMC Medicine | Issue 1/2009

Login to get access

Abstract

Background

Unprecedented declines in invasive breast cancer rates occurred in the United States between 2001 and 2004, particularly for estrogen receptor-positive tumors among non-Hispanic white women over 50 years. To understand the broader public health import of these reductions among previously unstudied populations, we utilized the largest available US cancer registry resource to describe age-adjusted invasive and in situ breast cancer incidence trends for non-Hispanic white women aged 50 to 74 years overall and by county-level rural/urban and poverty status.

Methods

We obtained invasive and in situ breast cancer incidence data for the years 1997 to 2004 from 29 population-based cancer registries participating in the North American Association of Central Cancer Registries resource. Annual age-adjusted rates were examined overall and by rural/urban and poverty of patients' counties of residence at diagnosis. Joinpoint regression was used to assess trends by annual quarter of diagnosis.

Results

Between 2001 and 2004, overall invasive breast cancer incidence fell 13.2%, with greater reductions among women living in urban (-13.8%) versus rural (-7.5%) and low- (-13.0%) or middle- (-13.8%) versus high- (-9.6%) poverty counties. Most incidence rates peaked around 1999 then declined after second quarter 2002, although in rural counties, rates decreased monotonically after 1999. Similar but more attenuated patterns were seen for in situ cancers.

Conclusion

Breast cancer rates fell more substantially in urban and low-poverty, affluent counties than in rural or high-poverty counties. These patterns likely reflect a major influence of reductions in hormone therapy use after July 2002 but cannot exclude possible effects due to screening patterns, particularly among rural populations where hormone therapy use was probably less prevalent.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356: 1670-1674. 10.1056/NEJMsr070105.CrossRefPubMed Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356: 1670-1674. 10.1056/NEJMsr070105.CrossRefPubMed
2.
go back to reference Jemal A, Ward E, Thun MJ: Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007, 9: R28-10.1186/bcr1672.CrossRefPubMedPubMedCentral Jemal A, Ward E, Thun MJ: Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007, 9: R28-10.1186/bcr1672.CrossRefPubMedPubMedCentral
3.
go back to reference Katalinic A, Rawal R: Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008, 107: 427-430. 10.1007/s10549-007-9566-z.CrossRefPubMed Katalinic A, Rawal R: Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008, 107: 427-430. 10.1007/s10549-007-9566-z.CrossRefPubMed
4.
go back to reference Robbins AS, Clarke CA: Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007, 25: 3437-3439. 10.1200/JCO.2007.11.4132.CrossRefPubMed Robbins AS, Clarke CA: Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007, 25: 3437-3439. 10.1200/JCO.2007.11.4132.CrossRefPubMed
5.
go back to reference Hausauer AK, Keegan TH, Chang ET, Clarke CA: Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. Breast Cancer Res. 2007, 9: R90-10.1186/bcr1839.CrossRefPubMedPubMedCentral Hausauer AK, Keegan TH, Chang ET, Clarke CA: Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. Breast Cancer Res. 2007, 9: R90-10.1186/bcr1839.CrossRefPubMedPubMedCentral
6.
go back to reference Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007, 99: 1335-1339. 10.1093/jnci/djm111.CrossRefPubMed Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007, 99: 1335-1339. 10.1093/jnci/djm111.CrossRefPubMed
7.
go back to reference Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99: 1152-1161. 10.1093/jnci/djm059.CrossRefPubMed Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99: 1152-1161. 10.1093/jnci/djm059.CrossRefPubMed
8.
go back to reference Cl CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ: Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006, 24: e49-50. 10.1200/JCO.2006.08.6504.CrossRef Cl CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ: Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006, 24: e49-50. 10.1200/JCO.2006.08.6504.CrossRef
9.
go back to reference Glass A, Hoover RN: Changing incidence of breast cancer. J Natl Cancer Inst. 1988, 80: 1076-1077.PubMed Glass A, Hoover RN: Changing incidence of breast cancer. J Natl Cancer Inst. 1988, 80: 1076-1077.PubMed
10.
go back to reference Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004, 291: 47-53. 10.1001/jama.291.1.47.CrossRefPubMed Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004, 291: 47-53. 10.1001/jama.291.1.47.CrossRefPubMed
11.
go back to reference Hillman JJ, Zuckerman IH, Lee E: The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. J Womens Health (Larchmt). 2004, 13: 986-992. 10.1089/jwh.2004.13.986.CrossRef Hillman JJ, Zuckerman IH, Lee E: The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. J Womens Health (Larchmt). 2004, 13: 986-992. 10.1089/jwh.2004.13.986.CrossRef
12.
go back to reference Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA: Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf. 2005, 14: 837-842. 10.1002/pds.1103.CrossRefPubMed Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA: Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf. 2005, 14: 837-842. 10.1002/pds.1103.CrossRefPubMed
13.
go back to reference Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L: Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004, 104: 1042-1050.CrossRefPubMed Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L: Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004, 104: 1042-1050.CrossRefPubMed
14.
go back to reference Wysowski DK, Governale LA: Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf. 2005, 14: 171-176. 10.1002/pds.985.CrossRefPubMed Wysowski DK, Governale LA: Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf. 2005, 14: 171-176. 10.1002/pds.985.CrossRefPubMed
15.
go back to reference Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML: Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008, 299: 1036-1045. 10.1001/jama.299.9.1036.CrossRefPubMed Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML: Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008, 299: 1036-1045. 10.1001/jama.299.9.1036.CrossRefPubMed
16.
go back to reference Health, United States, with chartbook on trends in the health of Americans. 2007, Statistics NCfH. Hyattsville, MD Health, United States, with chartbook on trends in the health of Americans. 2007, Statistics NCfH. Hyattsville, MD
17.
18.
go back to reference Breen NA, Cronin KA, Meissner HI, Taplin SH, Tangka FK, Tiro JA, McNeel TS: Reported drop in mammography: is this cause for concern?. Cancer. 2007, 109: 2405-2409. 10.1002/cncr.22723.CrossRefPubMed Breen NA, Cronin KA, Meissner HI, Taplin SH, Tangka FK, Tiro JA, McNeel TS: Reported drop in mammography: is this cause for concern?. Cancer. 2007, 109: 2405-2409. 10.1002/cncr.22723.CrossRefPubMed
20.
go back to reference Pfeiffer RM, Mitani A, Matsuno RK, Anderson WF: Racial differences in breast cancer trends in the United States (2000–2004). J Natl Cancer Inst. 2008, 100: 751-752. 10.1093/jnci/djn112.CrossRefPubMed Pfeiffer RM, Mitani A, Matsuno RK, Anderson WF: Racial differences in breast cancer trends in the United States (2000–2004). J Natl Cancer Inst. 2008, 100: 751-752. 10.1093/jnci/djn112.CrossRefPubMed
21.
go back to reference Clarke CA, Glaser SL: Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control. 2007, 18: 847-852. 10.1007/s10552-007-9029-1.CrossRefPubMed Clarke CA, Glaser SL: Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control. 2007, 18: 847-852. 10.1007/s10552-007-9029-1.CrossRefPubMed
22.
go back to reference Wei F, Miglioretti DL, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, Buist DS: Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr. 2005, 106-112. 10.1093/jncimonographs/lgi047. Wei F, Miglioretti DL, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, Buist DS: Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr. 2005, 106-112. 10.1093/jncimonographs/lgi047.
25.
go back to reference Willett WC, Rockhill B, Hankinson SE, Hunter DJ, Colditz G: Nongenetic factors in the causation of breast cancer. Diseases of the Breast. Edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. 2004, Philadelphia: Lippincott, Williams and Wilkins, 253-3 Willett WC, Rockhill B, Hankinson SE, Hunter DJ, Colditz G: Nongenetic factors in the causation of breast cancer. Diseases of the Breast. Edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. 2004, Philadelphia: Lippincott, Williams and Wilkins, 253-3
26.
go back to reference Wang D, Dubois RN: Cyclooxygenase-2: a potential target in breast cancer. Seminars in Oncology. 2004, 31 (1 Suppl 3): 64-73. 10.1053/j.seminoncol.2004.01.008.CrossRefPubMed Wang D, Dubois RN: Cyclooxygenase-2: a potential target in breast cancer. Seminars in Oncology. 2004, 31 (1 Suppl 3): 64-73. 10.1053/j.seminoncol.2004.01.008.CrossRefPubMed
28.
go back to reference Singh GK, Miller BA, Hankey BF, Edwards BK: Area socioeconomic variation in U.S. cancer incidence, mortality, stage, treatment, and survival, 1975–1999. NCI Cancer Surveillance Monograph Series, Number 4. 2003, Bethesda, MD: National Cancer Institute Singh GK, Miller BA, Hankey BF, Edwards BK: Area socioeconomic variation in U.S. cancer incidence, mortality, stage, treatment, and survival, 1975–1999. NCI Cancer Surveillance Monograph Series, Number 4. 2003, Bethesda, MD: National Cancer Institute
29.
go back to reference Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK, Eds: SEER Cancer Statistics Review, 1975–2004. 2007, Bethesda, MD: National Cancer Institute Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK, Eds: SEER Cancer Statistics Review, 1975–2004. 2007, Bethesda, MD: National Cancer Institute
30.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000, 19: 335-351. 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z.CrossRefPubMed Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000, 19: 335-351. 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z.CrossRefPubMed
31.
go back to reference Devesa SS, Donaldson J, Fears T: Graphical presentation of trends in rates. Am J Epidemiol. 1995, 141: 300-304.CrossRefPubMed Devesa SS, Donaldson J, Fears T: Graphical presentation of trends in rates. Am J Epidemiol. 1995, 141: 300-304.CrossRefPubMed
32.
go back to reference Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004, 140: 184-188.CrossRefPubMed Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004, 140: 184-188.CrossRefPubMed
33.
go back to reference Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998, 280: 605-613. 10.1001/jama.280.7.605.CrossRefPubMed Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998, 280: 605-613. 10.1001/jama.280.7.605.CrossRefPubMed
34.
go back to reference Fitzpatrick LA, Litin SC, Bell MR: The Women's Health Initiative: a heart-to-HRT conversation. Mayo Clin Proc. 2000, 75: 559-561.CrossRefPubMed Fitzpatrick LA, Litin SC, Bell MR: The Women's Health Initiative: a heart-to-HRT conversation. Mayo Clin Proc. 2000, 75: 559-561.CrossRefPubMed
35.
go back to reference Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA: Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf. 2005, 14: 837-842. 10.1002/pds.1103.CrossRefPubMed Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA: Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf. 2005, 14: 837-842. 10.1002/pds.1103.CrossRefPubMed
36.
go back to reference Haas JS, Miglioretti DL, Geller B, Buist DS, Nelson DE, Kerlikowske K, Carney PA, Dash S, Breslau ES, Ballard-Barbash R: Average household exposure to newspaper coverage about the harmful effects of hormone therapy and population-based declines in hormone therapy use. J Gen Intern Med. 2007, 22: 68-73. 10.1007/s11606-007-0122-7.CrossRefPubMedPubMedCentral Haas JS, Miglioretti DL, Geller B, Buist DS, Nelson DE, Kerlikowske K, Carney PA, Dash S, Breslau ES, Ballard-Barbash R: Average household exposure to newspaper coverage about the harmful effects of hormone therapy and population-based declines in hormone therapy use. J Gen Intern Med. 2007, 22: 68-73. 10.1007/s11606-007-0122-7.CrossRefPubMedPubMedCentral
37.
38.
go back to reference Gapstur SM, Morrow M, Sellers TA: Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA. 1999, 281: 2091-2097. 10.1001/jama.281.22.2091.CrossRefPubMed Gapstur SM, Morrow M, Sellers TA: Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA. 1999, 281: 2091-2097. 10.1001/jama.281.22.2091.CrossRefPubMed
39.
go back to reference Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed
40.
go back to reference Caan B, Habel L, Quesenberry C, Kushi L, Herrinton L: Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008, 100: 597-598. 10.1093/jnci/djn079. author reply 599CrossRefPubMed Caan B, Habel L, Quesenberry C, Kushi L, Herrinton L: Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008, 100: 597-598. 10.1093/jnci/djn079. author reply 599CrossRefPubMed
41.
go back to reference Krieger N, Chen JT, Waterman PD, Rehkopf DH, Yin R, Coull BA: Race/ethnicity and changing US socioeconomic gradients in breast cancer incidence: California and Massachusetts, 1978–2002 (United States). Cancer Causes Control. 2006, 17: 217-226. 10.1007/s10552-005-0408-1.CrossRefPubMed Krieger N, Chen JT, Waterman PD, Rehkopf DH, Yin R, Coull BA: Race/ethnicity and changing US socioeconomic gradients in breast cancer incidence: California and Massachusetts, 1978–2002 (United States). Cancer Causes Control. 2006, 17: 217-226. 10.1007/s10552-005-0408-1.CrossRefPubMed
42.
go back to reference Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE: The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988–1994. Menopause. 2002, 9: 264-272. 10.1097/00042192-200207000-00007.CrossRefPubMed Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE: The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988–1994. Menopause. 2002, 9: 264-272. 10.1097/00042192-200207000-00007.CrossRefPubMed
43.
go back to reference Brett KM, Madans JH: Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol. 1997, 145: 536-545.CrossRefPubMed Brett KM, Madans JH: Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol. 1997, 145: 536-545.CrossRefPubMed
44.
go back to reference Robbins AS, Clarke CA: Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007, 99: 1815-author reply 1816–1817CrossRefPubMed Robbins AS, Clarke CA: Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007, 99: 1815-author reply 1816–1817CrossRefPubMed
45.
go back to reference Vaidya JS: Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008, 100: 598-599. 10.1093/jnci/djn080. author reply 599CrossRefPubMed Vaidya JS: Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008, 100: 598-599. 10.1093/jnci/djn080. author reply 599CrossRefPubMed
46.
go back to reference Cady B, Chung MA, Michaelson JS: A decline in breast-cancer incidence. N Engl J Med. 2007, 357: 511-author reply 513PubMed Cady B, Chung MA, Michaelson JS: A decline in breast-cancer incidence. N Engl J Med. 2007, 357: 511-author reply 513PubMed
47.
go back to reference Singh GK, Miller BA, Hankey BF, Feuer EJ, Pickle LW: Changing area socioeconomic patterns in U.S. cancer mortality, 1950–1998: Part I – all cancers among men. J Natl Cancer Inst. 2002, 94: 904-915.CrossRefPubMed Singh GK, Miller BA, Hankey BF, Feuer EJ, Pickle LW: Changing area socioeconomic patterns in U.S. cancer mortality, 1950–1998: Part I – all cancers among men. J Natl Cancer Inst. 2002, 94: 904-915.CrossRefPubMed
48.
go back to reference Singh GK, Miller BA, Hankey BF: Changing area socioeconomic patterns in U.S. cancer mortality, 1950–1998: Part II – lung and colorectal cancers. J Natl Cancer Inst. 2002, 94: 916-925.CrossRefPubMed Singh GK, Miller BA, Hankey BF: Changing area socioeconomic patterns in U.S. cancer mortality, 1950–1998: Part II – lung and colorectal cancers. J Natl Cancer Inst. 2002, 94: 916-925.CrossRefPubMed
49.
go back to reference Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R: Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project. Am J Epidemiol. 2002, 156: 471-482. 10.1093/aje/kwf068.CrossRefPubMed Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R: Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project. Am J Epidemiol. 2002, 156: 471-482. 10.1093/aje/kwf068.CrossRefPubMed
50.
go back to reference Krieger N, Williams DR, Moss NE: Measuring social class in US public health research: concepts, methodologies, and guidelines. Annu Rev Public Health. 1997, 18: 341-378. 10.1146/annurev.publhealth.18.1.341.CrossRefPubMed Krieger N, Williams DR, Moss NE: Measuring social class in US public health research: concepts, methodologies, and guidelines. Annu Rev Public Health. 1997, 18: 341-378. 10.1146/annurev.publhealth.18.1.341.CrossRefPubMed
51.
go back to reference Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
Metadata
Title
Recent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status
Publication date
01-12-2009
Published in
BMC Medicine / Issue 1/2009
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-7-31

Other articles of this Issue 1/2009

BMC Medicine 1/2009 Go to the issue